All News

Aurelie Najm Tweet
RA males 81% increase MACE & 58% ischemic CVE 2 folds Males>Females in MTX non users Makes MTX users reduction 66% & 55% risk MACE & ischemic CVE and no diff w/ females MTX use not assoc w/ reduction MACE in females @RheumNow #ACR23 ABST1627 https://t.co/qbAc2bWdcM
Dr. John Cush Tweet
RheumNow
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Mike Putman Tweet
EBRheum
SMART study in RA, splitting MTX Split dosing better at wk 16 but ~similar at wk 24 Caveat: wonky design from wk16-wk24 makes it hard to interpret? Surprsingly, adverse events ~similar but smallish sample Mostly supports my practice of splitting? @RheumNow #ACR23 #ACRBest https://t.co/g7s4EUHeCW
Richard Conway Tweet
SMART study - MTX split into morning and evening once weekly vs all together. 253 patients. Split dosing better efficacy (DAS28 4.1 vs 4.5, p=0.03), more LFT elevation but less neutropenia. Abstr#1583 #ACR23 @RheumNow https://t.co/tkrds4uqQP
Dr. Rachel Tate Tweet
#ACR23 Abs #1641 found early referral & dx in PsA associated w/ better clinical outcomes. MDA & DAPSA remission over 3 years less likely after > 52 weeks from symptom onset to dx. Likely delays in females w/ less swollen joints & lower CRP/ ESR https://t.co/meVQ1UisKY @rheumnow https://t.co/EBN7wJfjzK
Aurelie Najm Tweet
Split dose oral MTX (15/10mg) versus single dose (25mg) in RA RCT 250pts EULAR good resp 16wks 22 vs 10% (sig) 24wks 37 vs 28% (ns) 50% more addition of 2nd csDMARD in single dose #ACRBest @RheumNow #ACR23 ABST1583 For more thoughts, have a read https://t.co/urA6X4rY0D 👇🏼
Eric Dein Tweet
SMART on MTX Ab#1583 @RheumNow #ACR23 Single dose MTX 25 mg v Split dose (same day 15/10 mg). FA 5 mg 2x/wk. 16w can add csDMARD Split 29% vs 22% - EULAR response improve - not signif. Better DAS28 Split: 35% added 2nd csDMARD vs. 54.5% in single dose No stat diff in sAE #ACRBest
Dr M Nazibur Rahman, MD (Rheumatology) Tweet
with The @RheumNow John Cush #ACR23 https://t.co/muRAOn3Cb9
Md Yuzaiful Md Yusof Tweet
#ACR23 Abstr#1479 In N=66 patients with #SLE, 29% had high risk HPV infection. Associated with lupus disease duration. In 2nd screening ~1yr after, multiple infections occurred in 15%, about similar vs women with HIV. Call to promote HPV vaccination in SLE 💉 @RheumNow https://t.co/UGIrCwu32x
Robert B Chao, MD Tweet
Should Methotrexate be prescribed as split dosing? Multi-center, RCT of RA pts showed split dosing of 25mg MTX resulted in higher efficacy + reduced need for additional DMARDs, compared to single dose MTX @RheumNow #ACR23 Abs#1583 https://t.co/zjjnzWUl5E
sheila Tweet
Dr. AMendel et al:TMP-SMX prophylaxis assoc w⬇️serious infexns in RTX treated GPA pts; BL (aHR 0.5;95%CI 0.3-0.8) & time-varying exposure (aHR 0.5; 95%CI 0.3-0.9) A good thing to consider but weigh benefits/harms w/TMP-SMX prophy. More studies req'd? #ACR23 ABST1584 @RheumNow https://t.co/dfsfpcQu2A
Dr. Rachel Tate Tweet
Izokibep, IL-17Ai, #ACR23 abs #1688 demonstrated ACR70 in 52%, PASI100 in 71% and enthesitis complete resolution in 89% at week 46. Well tolerated, no dose-related AEs, similar safety with other IL-17Ai https://t.co/TQAIVa9H2j @rheumnow https://t.co/ihzxnuAsWw
Richard Conway Tweet
TMP-SMX in AAV with RTX. 919 patients. Only given to 31% (40% on steroid>20mg), what!? TMP-SMX aHR 0.5 for serious infection, aHR 0.7 for minor infection. PJP 13 vs 0. Abstr#1584 #ACR23 @RheumNow https://t.co/4YQELIC82F https://t.co/U5l5KzSkB5
Dr. Rachel Tate Tweet
MOSAIC study: #ACR23 Abs #1690 finds APR reduces clinical and objective MRI indices in PsA, confirming an effect of APR on clinical and inflammatory manifestations of PsA. https://t.co/F5D81FF1tj @rheumnow https://t.co/rGglgiOyDg
Eric Dein Tweet
TMP-SMX PPx in GPA A#1584 @RheumNow #ACR23 919 pt analyzed TMP-SMX ass w/ decr serious ifn (HR 0.5), less outpt ifns (0.9) Rates for AEs attrib to TMP-SMX per 100 py: 29.6, wo TMP-SMX: 13.4 13 PJP, all in non-TMP-SMX pts Should we use Bactrim to prevent ifn beside PJP? GC effects
Md Yuzaiful Md Yusof Tweet
#ACR23 Abstr#1584 Data N=919 pts with GPA vasculitis treated with rituximab showed Septrin prophylaxis (+/- 28days of RTX) reduced serious & any infection. PJP=1.4% not on septrin. Question remains re: how long for in those receiving repeat cycles & steroid confounding @RheumNow https://t.co/81f8hbMids
Aurelie Najm Tweet
What is frailty? How does it affect RA outcomes? Pop based cohort study 13000+ RA vs. 26000+ matched ctrl Over 2x more frailty 5.6% vs 2.6% OR frailty in RA 2.3 Adjusted for rurality, neighborhood income quartiles AND BL comorbidities index @RheumNow #ACR23 ABST1275 https://t.co/ZkOpgHPSE0
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×